Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T cell lymphoma

Imagem de Miniatura
Arquivos
art_LAGE_Absolute_monocyte_count_is_a_predictor_of_overall_2019.PDF (419.87 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
MOREIRA, Frederico Rafael
Citação
ANNALS OF HEMATOLOGY, v.98, n.9, p.2097-2102, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Nodal peripheral T cell lymphomas (nPTCL) present aggressive clinical course, and its heterogeneous nature and poor prognosis with current therapeutic strategies make it a target for the development of new prognostic markers. Thus, we investigated tumor-associated macrophages (TAM) according to the number of cells expressing CD68 in biopsies and the absolute monocyte count (AMC) in peripheral blood of 87 patients with nPTCL. The median overall survival (OS) was 3 years (95% CI 1.3-8.4 years) and estimate 5 years OS of 43.3% (95% CI 32.5-53.7%). The median progression-free survival (PFS) was 1.5 years (95% CI 0.8-2.6 years) with estimate 5 years PFS of 29.2% (95% CI 19.7-39.3%). The cutoff for AMC was 1.5 x 10(9)/L and the median OS for patients with AMC >= 1.5 x 10(9)/L was 0.83 years versus 3.7 years for those with AMC < 1.5 x 10(9)/L (HR 2.32, 95% CI 1.03-5.22, p = 0.035). The median PFS for patients with AMC >= 1.5 x 10(9)/L was 0.50 years versus 1.5 years for those with AMC < 1.5 x 10(9)/L (HR 2.25, 95% CI 1.05-4.78, p = 0.031). CD68 was evaluated in 26/87 (29.8%) patients with a median expression of 34% and positivity cutoff of 43%. CD68 expression was not associated with OS or PFS either with AMC values. Our findings suggest that the AMC of >= 1.5 x 10(9)/L at diagnosis in peripheral blood is associated with poor prognosis in nPTCL. Further investigations in a larger cohort are required to better validate our results.
Palavras-chave
Nodal peripheral T cell lymphoma, Absolute monocyte count, Tumor-associated macrophages, Prognosis
URI
https://observatorio.fm.usp.br/handle/OPI/33925
Referências
  1. Ansell Stephen M, 2013, Am Soc Clin Oncol Educ Book, DOI 10.1200/EdBook_AM.2013.33.e91
  2. Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800
  3. Farinha P, 2005, BLOOD, V106, P2169, DOI 10.1182/blood-2005-04-1565
  4. Foss FM, 2012, HEMATOLOGY, V117, P6756
  5. Hui LL, 2015, CANCER LETT, V368, P7, DOI 10.1016/j.canlet.2015.07.039
  6. Jia T, 2018, CANCER BIOMARK, V22, P807, DOI 10.3233/CBM-181505
  7. Li N, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705503
  8. Li Q, 2018, LEUKEMIA RES, V73, P5, DOI 10.1016/j.leukres.2018.07.020
  9. Niino D, 2010, PATHOL INT, V60, P278, DOI 10.1111/j.1440-1827.2010.02514.x
  10. Pedersen MB, 2014, HISTOPATHOLOGY, V65, P490, DOI 10.1111/his.12407
  11. SHIPP MA, 1994, BLOOD, V83, P1165
  12. Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680
  13. Swerdlow SH, 2016, WHO CLASSIFICATION T
  14. Tadmor T, 2014, HAEMATOLOGICA, V99, P125, DOI 10.3324/haematol.2013.088161
  15. von Hohenstaufen KA, 2013, BRIT J HAEMATOL, V162, P465, DOI 10.1111/bjh.12409
  16. Wang H, 2015, ANN HEMATOL, V94, P1535, DOI 10.1007/s00277-015-2401-4
  17. Wilcox RA, 2009, BLOOD, V114, P2936, DOI 10.1182/blood-2009-05-220111
  18. Yang YQ, 2016, LEUKEMIA RES, V42, P88, DOI 10.1016/j.leukres.2015.12.010
  19. Zhang W, 2011, LEUKEMIA LYMPHOMA, V52, P46, DOI 10.3109/10428194.2010.529204

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/31
Carregar mais